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Amyotrophic lateral sclerosis (ALS) patients exhibit diverse pathologies such as endoplasmic reticulum
(ER) stress and mitochondrial dysfunction in motor neurons. Five to ten percent of patients have familial
ALS, a form of the disease caused by mutations in ALS-related genes, while sporadic forms of the disease
occur in 90e95% of patients. Recently, it was reported that familial ALS patients exhibit a missense
mutation in SIGMAR1 (c.304G > C), which encodes sigma-1 receptor (Sig-1R), substituting glutamine for
glutamic acid at amino acid residue 102 (p.E102Q). Expression of that mutant Sig-1RE102Q protein reduces
mitochondrial ATP production, inhibits proteasome activity and causes mitochondrial injury, aggravating
ER stress-induced neuronal death in neuro2A cells. In this issue, we discuss mechanisms underlying
mitochondrial impairment seen in ALS motor neurons and propose that therapies that protect mito-
chondria might improve the quality of life (QOL) of ALS patients and should be considered for clinical
trials.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Amyotrophic lateral sclerosis and mitochondrial
dysfunction
Amyotrophic lateral sclerosis (ALS) is a progressive neurode-
generative disorder with upper and lower motor neuron deﬁcits.
This disease affects an estimated 1e2 individuals per 100,000 every
year. ALS can be manifested by muscle weakness and atrophy,
fasciculations, paralysis, swallowing disorders and respiratory
dysfunction. Symptoms progress rapidly after disease onset, and
half of all patients die within 3e5 years (1). ALS is classiﬁed as
sporadic (SALS; ~90e95%) or familial (FALS; ~5e10%) (2,3). The
cause of SALS is largely unknown but assumed to include genetic
and environmental factors, while, genetic factors underlying FALS
have been reported and account for approximately 70% of those
cases (4). One dominant mutation in the superoxide dismutase 1
(SOD1) gene was ﬁrst identiﬁed in FALS patients, and so far, over
one hundred SOD mutations have been deﬁned (4,5). SOD1cology, Graduate School of
maki Aoba, Aoba-ku, Sendai
unaga).
acological Society.
. Production and hosting by Elsefunctions in removal of reactive oxygen species (ROS) that induce
mitochondrial dysfunction and apoptosis (6). In fact, spinal motor
neuron loss is a major pathology seen in ALS patients and, model
mice (7). Transgenic model mice harboring the human SOD1G93A
mutation have been extensively analyzed, greatly enhancing our
understanding of ALS pathology. Most SOD1 mutations are asso-
ciated with loss of its enzymatic activity; however, in contrast to
SOD1G93Amodel mice, SOD1 null mice exhibit normal motor
neuron development and function until they are at least until 6
months old, suggesting that SOD1 loss of function is not a direct
cause of ALS onset (8,9).
SOD1G93Amutant protein localizes tomitochondria by forming a
complex with Bcl-2 (10,11). Bcl-2 functions to inhibit apoptosis by
regulating both cytochrome c release from mitochondria and cas-
pase activation. Pasinelli et al reported that SOD1G93A forms ag-
gregates with Bcl-2 in the spinal cord but not in the liver of model
mice (11). This is an interesting observation because Bcl-2 null mice
show degeneration of motor, sensory and sympathetic neurons
(12). By contrast, genetic deletion of either the pro-apoptotic fac-
tors Bax or Bak in SOD1G93A mice inhibits motor neuron degener-
ation and promotes mouse survival (13). Similarly, perturbed ER-
mitochondria interaction was observed in embryonic motor neu-
rons from SOD1G93A mutant mice (14). Taken together,vier B.V. This is an open access article under the CC BY-NC-ND license (http://
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moted by SOD1G93A.
Mitochondria are also crucial for regulation of cell calcium ho-
meostasis and energy production through the tricarboxylic acid
(TCA) cycle, the electron transport chain and ATP synthase. Both
mitochondrial ﬁssion and fusion are impaired in ALS patients.
Mitochondrial ﬁssion/fusion directly or indirectly inﬂuence mito-
chondrial energy metabolism. Knock-out or down-regulation of
ﬁssion or fusion proteins reduces mitochondrial respiration and
ATP generation (15). In addition, decreased mitochondrial calcium
transport through the mitochondrial calcium uniporter (MCU) is
observed in brainstem neurons of aging SOD1G93A mice (16).
Consistent with these ﬁndings, levels of stored mitochondrial cal-
cium decline in these neurons (17). However, mechanisms under-
lying mitochondrial impairment due to expression of ALS-related
genes are largely unknown.
Sig-1R is an ER-resident chaperone protein that localizes pre-
dominantly to the mitochondrial-associated ER membrane (MAM),
where Sig-1R stimulation promotes calcium transport into mito-
chondria through the IP3 receptor (18). Indeed, IP3 production
following stimulation of G protein-coupled receptors (GPCRs)Fig. 1. Intracellular localization of overexpressed Sig-1R- or Sig-1RE102Q-mCherry pro
localization of Sig-1R or Sig-1RE102Q (red) and the mitochondrial marker cytochrome c (gre
methyl pyruvate (MP) or Ru360 for 48 h. Each column represents the mean ± S.E.M. *, P < 0
cells; yy, P < 0.01 versus Sig-1RE102Q-transfected cells; ¶¶, P < 0.01 versus s1RE102Q-transfeenhances mitochondrial calcium transport and ATP production in
neurons and cardiomyocytes (19, 20). Furthermore, the physio-
logical relevance of Sig-1R in neuropsychotherapeutic drug actions
is well documented in the current issue (21,22). The pathophysio-
logical relevance of Sig-1R in neurodegenerative disorders and ALS
is also extensively discussed in the present issue (23,24). Recently, a
missense mutation in SIGMAR1 causing substitution of glutamine
for glutamic acid at Sig-1R amino acid residue 102 (p.E102Q) was
reported in juvenile FALS patients (25). To determine whether ALS-
related SIGMAR1 mutations cause mitochondrial impairment in
neurons, we transfected neuro2A cells with a construct encoding
either wild-type Sig-1R or the p.E102Q mutant (Sig-1RE102Q) and
assessed mitochondrial function (26). Sig-1RE102Q mutant caused
dissociation of Sig-1RE102Q proteins from the ER membrane and its
subsequent cytoplasmic aggregation (Fig. 1A). We also observed
disrupted mitochondrial structure following Sig-1RE102Q expres-
sion, as assessed by cytochrome c staining, an effect not seen after
expression of the wild-type protein. Mitochondrial damage pre-
ceded autophagic cell death, as assessed by LC3-II formation (26).
Aberrant mitochondrial morphology is associated with reduced
ATP production. ATP is required not only for cell metabolism butteins in transfected Neuro2A cells. (A) Immunoﬂuorescence showing intracellular
en). (B) Measurement of proteasome activity with or without tunicamycin (2 mg/ml),
.05 and **, P < 0.01 versus control cells (Cont); #, P < 0.05 versus tunicamycin-treated
cted and tunicamycin-treated cells. Modiﬁed from (20).
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neuro2A cells led to reduced proteasome activity, especially under
ER stress conditions such as tunicamycin treatment (Fig. 1B).
Likewise, treatment of neuro2A cells with Ru360, a mitochondrial
calcium uniporter inhibitor, reduced both ATP production and
proteasome activity (Fig. 1B). Treatment of neuro2A cells with
methyl pyruvate (MP), which increases ATP production, totally
rescued proteasome activity, even under ER stress conditions (26).
Moreover, s1RE102Q-overexpressing cells showed aberrant extra-
nuclear localization of the TAR DNA-binding protein (TDP-43), a
condition exacerbated by tunicamycin-dependent ER stress (Fig. 2)
and partly due to reduced mitochondrial Ca2þ transport and ATP
production. TDP-43 extra-nuclear localization was also associated
with formation of cellular inclusion bodies and TDP-43 hyper-
ubiquitination (26) (Fig. 3). However, it is remains unclear whether
or how TDP-43 extra-nuclear localization promotes mitochondrial
damage seen in ALS patients.
TDP-43-positive inclusions in the cytosol of motor neurons have
been observed in almost all ALS patients (27). TDP-43 was ﬁrst
identiﬁed as a protein binding to the human immunodeﬁciency
virus type-1 (HIV-1) long terminal repeat (TAR), thereby regulating
HIV-1 gene expression (28). Subsequently, two groups simulta-
neously reported the appearance of aberrant TDP-43-positive
cytosolic inclusions and skein-like inclusions in the spinal cord,
hippocampus and neocortex in tissue samples from patients with
frontotemporal lobar degeneration (FTLD) and in the spinal cord of
ALS patients (29,30). Those investigators also documented that
TDP-43 is subject to posttranslational modiﬁcations, such as
hyperphosphorylation, ubiquitination or cleavage of its C-terminal
fragments. In 2008, investigators reported TDP-43 mutations in
FALS and SALS patients (31). TDP-43 exhibits both a nuclearFig. 2. Effect of tunicamycin treatment and Sig-1RE102Q overexpression on TDP-43 mislo
Sig-1RE102Q (red) in the presence or absence of tunicamycin (ER stress inducer) in Neuro2A
from (20).localization signal and a nuclear export signal, enabling it to shuttle
between the nucleus and cytosol. It also harbors a glycine-rich re-
gion serving as prion-like domain in its C-terminus, where most
pathological mutations reside. Physiological functions of TDP-43
include: i) translational repression, ii) regulation of splicing, iii)
RNA transport and formation of stress granules through binding
with the 30UTR of RNA, and iv) regulation of microRNA activity (27).
Genome-wide RNA immunoprecipitation analysis revealed that
TDP-43 binds at least 6000 RNA targets and can occupy more than
40,000 RNA binding sites in brain (27). Moreover, TDP-43 knock-
down by RNA interference in vivo alters expression of over 600
RNAs and splicing of over 950 in mouse brain (32). Among them,
genes down-regulated following TDP-43 knockdown include those
encoding the L-type voltage-dependent calcium channel, IP3 re-
ceptor type 1, ryanodine receptor 2 and calcium/calmodulin-
dependent protein kinase IV, all associated with synaptic trans-
mission and/or calcium homeostasis (32, 33). Genes up-regulated
following TDP-43 knockdown function in lysosomal degradation,
which is associated with immune defense and inﬂammatory sys-
tems (32). Overexpression of TDP-43Q331K or TDP-43M337V mutants
in rat primary motor neurons results in shortening of mitochondria
in dendrites and axons, cell compartments also exhibiting
abnormal mitochondrial transport (34). Interestingly, TDP-43Q331K
or TDP-43M337V mutant proteins preferentially co-localize with
mitochondria in axons and dendrites unlike nuclear localization of
wild-type TDP-43 protein, suggesting that TDP-43 mutants likely
bind to mitochondria in neurons (34). Moreover, wild-type TDP-43,
TDP-43Q331K or TDP-43M337V overexpressed in cells of the motor
neuron line NSC-34 localizes to mitochondrial membranes and
promotes reduction in mitochondrial membrane potential and
complex I activity. Mitochondrial localization of TDP-43 is closelycalization. Confocal analyses were carried out with or without transfection of Sig-1R or
cells. Cells were also stained with TDP-43 antibody (green) and DAPI (blue). Modiﬁed
Fig. 3. Working hypothesis Sig-1RE102Q mutant in ALS pathology. Under ER stress conditions, Sig-1RE102Q dissociates from the ER and aggregates in the cytoplasm. Loss of the Sig-
1R/IP3R association impairs mitochondrial Ca2þ transport, reduces Ca2þ-dependent ATP production and disturbs proteasome activity. Mislocalization and hyper-ubiquitination of
TDP-43 in the cytosol may further impair mitochondrial and autophagosome function. IP3R3: IP3 receptor type 3, TDP-43: TAR DNA-binding protein. Modiﬁed from (20).
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Furthermore, NSC-34 cells overexpressing TDP-35 and TDP-25,
which are respective 35 and 25 kDa C-terminal fragments of TDP-
43, show co-localization of the mutant protein with mitochondria
and mitochondrial dysfunction and mitophagy (35). Membranes of
the ER and mitochondria are closely associated via proteineprotein
interactions between Mfn1/Mfn2 or VAPB/PTPIP51 (37,38). Stoica
et al. reported that overexpression of wild-type or TDP-43 mutants
(M337V, Q331K, A382T and G348C) in NSC-34 cells interferes with
VAPB/PTPIB51 interaction and disrupts ER-mitochondria junctions.
These activities also occur in motor neurons of TDP-43-
overexpressing transgenic mice (39). Transgenic mice over-
expressing either wild-type or mutant forms of TDP-43 show
abnormal cytoplasmic localization of phosphorylated and ubiq-
uitinated inclusions in neurons of the spinal cord, cortex and hip-
pocampus (40e43). Like SOD1G93A mice, transgenic mice
overexpressing wild-type or mutant TDP-43 also exhibit mito-
chondrial aggregation in spinal motor neurons (40,41). Similarly, in
mice, knock-in of the human TDP-43A315T mutant promotes for-
mation of ubiquitin-positive inclusion bodies containing TDP-43 in
the spinal cord and abnormal mitochondrial structure in motor
cortex neurons (44). Taken together, aberrant cytosolic localization
of either wild-type or mutant forms of TDP-43 directly impairs
mitochondrial function.
2. Aberrant mitochondrial function in other ALS models
Ferri et al. has reported that SOD1G93A overexpression, but not
overexpression of wild-type SOD1, in NSC-34 cells induces mito-
chondrial fragmentation associated with both up-regulation of
mitochondrial ﬁssion protein Drp1 and down-regulation of fusion
protein Opa1 (45). SOD1G93A expression also induced aberrant
mitochondrial macrostructure, such as swelling, abnormal cristae
and vacuolization, in NSC-34 cells (46). Dominant mutations in
other genes including TAR DNA-binding protein 43 (TARDBP), FUS
RNA-binding protein (FUS), ubiquilin 2 (UBQL2), sequestosome 1
(SQSTM1, p62), and optineurin (OPTN) are causative of FALS
(31,47e51). Like TDP-43, FUS is DNA/RNA binding proteins regu-
lating RNA translation, splicing and stability. Transgenic ratsharboring human FUS, as well as TARDBP transgenic mice, report-
edly show aggregation of abnormal mitochondria in entorhinal
cortical neurons (52). UBQL2 and SQSTM1 gene products regulate
proteasomal and autophagic degradation of ubiquitinated proteins,
respectively (53,54). OPTN and SQSTM1 gene products function in
mitochondrial quality control by regulating degradation of
damaged mitochondria. Wong and Holzbaur also reported that the
wild-type OPTN gene product, but not its ALS-related mutant
E478G, localizes to mitochondria following mitochondrial depo-
larization, suggesting that removal of impaired mitochondria is
dysregulated in ALS (55).
3. Disease-modifying ALS therapies
Pre-clinical studies targeting mitochondria and oxidative stress
have been carried out using the SOD1G93A model mice, and several
potential therapeutics have been proposed (56e58). Riluzole, the
only agent approved to treat ALS in Japan, is thought to exert a
neuroprotective effect by blocking voltage-dependent cation
channels, preventing neuronal hyperactivity and glutamate exci-
totoxicity (59). However, riluzole effects are limited as prolonging
survival for only a few months, and the drug has little effect in
delaying or ameliorating symptoms. Thus, disease-modifying
therapeutics are still required to improve QOL of patients. We
have noted that Sig-1R null mice aggravate neuropathology in
SOD1G94A mice, thereby reducing longevity of the mice (60). In
motor neurons, subsurface cisternae of the ER, a region where Sig-
1R interacts with IP3R type 3, show enrichment in Sig-1R. Calcium
release from IP3R may promote conductance of potassium channels
such as small conductance calcium-activated potassium channels
(SK) channels (61). Those authors proposed that the loss of Sig-1R-
regulated SK channel activation in Sig-1R null mice increases motor
neuron excitability, leading to cell death. These experiments also
suggest that Sig-1R agonists could have beneﬁcial effects for ALS
patients. As expected, administration of the Sig-1R agonist PRE-084
(0.25 mg/kg) to 8 to 16-week-old SOD1G94A mice signiﬁcantly
extended their survival by more than 15% and delayed disease
onset in both male and female mice. Extended motor neuron sur-
vival was associated with protein kinase C-dependent
K. Fukunaga et al. / Journal of Pharmacological Sciences 127 (2015) 36e4140phosphorylation of the NR1 subunit of the NMDA receptor and
decreased microglial activity (62). Similarly, Peviani et al. reported
that chronic treatment of mice with PRE-084, starting at symptom
onset, signiﬁcantly increased levels of brain-derived neurotrophic
factor (BDNF) in gray matter and improved motor neuron survival
(63). PRE-084 treatment was also associated with reduction in the
number of reactive astrocytes and increases in CD11bþ microglial
cells. These ﬁndings were conﬁrmed by treatment of SOD1G94A
mice with a different Sig-1R agonist, SA4503 (64). Given that
mitochondrial damage likely underlies neurodegeneration seen in
ALS, therapy that rescues that damage could constitute potential
therapy. To test this hypothesis, we treated cultured neuro2A cells
overexpressing Sig-1RE102Q with methyl pyruvate (5 mM) as a sub-
strate of TCA cycle (26) and observed rescued ATP production,
which is down-regulated in those cells. Notably, similar methyl
pyruvate treatment also rescued proteasome activity and extra-
nuclear TDP-43 localization in those cells. Administration of so-
dium pyruvate (1000 mg/kg/week) from disease onset also
extended lifespan of SOD1G94A mice by 12.3 days (65). Although
this survival effect was small, combination treatment with both
Sig-1R agonists and methyl pyruvate may prove to be more effec-
tive and warrants analysis.
4. Conclusion
Sig-1R is a potential therapeutic target in neurodegenerative
diseases. Here, we propose that Sig-1R agonists possess potential
neuroprotective activity. In ER stress conditions in particular, Sig-1R
stimulation promotes mitochondrial Ca2þ transport from the ER
and mitochondrial ATP production. ATP production may in turn be
crucial for proteasome activity, which is essential to degrade
abnormal, mislocalized proteins under ER and oxidative stresses.
Although Sig-1R agonists would not be beneﬁcial for forms of ALS
harboring Sig-1R mutations, combination treatment with Sig-1R
agonists and pyruvate could serve as potential therapy for ALS
patients. Since clinical trials using sodium pyruvate to treat mito-
chondrial DNA depletion syndrome are now under way (66) and
potent Sig-1R agonists such as ﬂuvoxamine are clinically available
(67), these combination therapies to treat ALS could soon be eval-
uated in the clinical settings.Conﬂict of interest statement
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